Galapagos NV Logo

Galapagos NV

A biotechnology company focused on a rapid, decentralized cell therapy platform.

GLPG | BR

Overview

Corporate Details

ISIN(s):
BE0003818359
LEI:
549300QKJ78IY0IOV655
Country:
Belgium
Address:
Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen

Description

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-01-08 07:30
GLPG press release_ENG_FINAL CLEAN.pdf
English PDF 293.2 KB
2025-01-08 07:30
GLPG press release_NL_FINAL CLEAN.pdf
Dutch PDF 295.8 KB
2024-12-09 09:36
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD1…
Dutch PDF 274.9 KB
2024-12-09 09:36
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD1…
Dutch PDF 274.9 KB
2024-11-06 07:31
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at…
Dutch PDF 329.7 KB
2024-11-06 07:31
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at…
English PDF 262.0 KB
2024-10-31 07:49
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Up…
English PDF 471.8 KB
2024-10-31 07:49
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Up…
Dutch PDF 481.3 KB
2024-10-30 21:01
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Up…
English PDF 471.8 KB
2024-10-30 21:01
Galapagos rapporteert financiële resultaten over het derde kwartaal van 2024 en…
Dutch PDF 481.3 KB
2024-10-07 09:30
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic…
Dutch PDF 170.1 KB
2024-10-07 09:30
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic…
English PDF 166.9 KB
2024-10-01 07:41
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
English PDF 186.4 KB
2024-10-01 07:41
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
Dutch PDF 186.6 KB
2024-09-30 22:01
26092024 EcoR1 Capital Galapagos tr-1be-FINAL_Redacted (1).pdf
English PDF 1.1 MB

Automate Your Workflow. Get a real-time feed of all Galapagos NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galapagos NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Galapagos NV via our API.

Get Historical Data →

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.